{'fraction_non_alphanumeric': 0.021243115656963022, 'fraction_numerical': 0.01888276947285602, 'mean_word_length': 5.3283582089552235, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Differential expression, coding and non-coding, of FGF14 in cancers of the breast.

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of an antisense RNA transcribed from the FGF14 locus, FGF14-AS2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. A coding FGF14 transcript was differentially expressed in the tumor cells of patients with triple negative breast cancer. FGF14-AS2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of FGF14-AS2 in primary tumors of the breast was correlated with distant metastasis-free survival in patients with HER2+ subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed antisense transcript and patient survival outcomes influenced by PAM50 molecular subtype. FGF14-AS2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.